Granza Bio Analysis: $7M Raised
What is Granza Bio?
Granza Bio develops precision shell technology to deliver immune-inspired therapeutic agents, targeting diseases such as cancer and infections.
Location
San Francisco, United States
Employees
5
Founded
2024
Revenue
$5M
Investors
- Felicis Ventures
- Y Combinator
- Refactor Capital
Product Features & Capabilities
- Precision shell technology, targeted therapeutic delivery, cancer treatment, autoimmune disease treatment, delivery of genetic modifiers, packaging of attack particles, RNAs, and proteins, overcoming immunological activation, targeting hard-to-reach organs.
Use Cases
Deliver therapeutic agents to specific tissues; Enhance treatment efficacy for cancer and autoimmunity; Package and deliver genetic modifiers; Target hard-to-reach organs for therapy; Overcome immune system activation challenges.
How much Granza Bio raised
Seed - $7M
July 3, 2024Lead Investor: Felicis and Y Combinator
Who are the founders of Granza Bio
AN
Ashwin Nandakumar
Founder
AJ
Ashwin Jainarayanan
Founder
Business Model
Seed funding from investors; revenue through therapeutic delivery partnerships and innovations.
Market Focus
Granza Bio primarily focuses on the biotechnology industry, specifically in the development of targeted therapeutic delivery systems for diseases such as cancer, autoimmunity, and infections using synthetic "precision shell" technology.
Competitors Overview
Granza Bio operates in the biotechnology sector, focusing on targeted therapeutic delivery systems for diseases like cancer and autoimmunity. Its main competitors include:
- Meditope Biosciences: This company develops antibody-drug conjugates (ADCs) for cancer treatment. Meditope's advantage l
See something that needs updating? Suggest edits to this profile.